Announcement PDF Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Neurizon Develops Liquid Formulation of NUZ-001 to Improve Patient Access and Experience Highlights:      Neurizon has successfully developed a new oral liquid formulation of NUZ-001 for the treatment of ALS The liquid formulation is designed to support patients with all stages of ALS, particularly those with swallowing difficulties such as bulbar onset, ensuring broader access to therapy Developed as part of Neurizon’s patient-centric innovation strategy, the liquid form enhances continuation of treatment, ease of administration, and overall treatment experience for patients with ALS Supports Neurizon’s life cycle management strategy to transform NUZ-001 from a single-asset product into a long-term scalable treatment platform and unlock patient and commercial value Integration into Neurizon’s ongoing clinical development program for NUZ-001 has commenced, with a human bioequivalence study alongside the standard tablet form, scheduled to begin in H1 CY 2026 26 June 2025 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the development of a new oral liquid formulation of NUZ-001, its lead investigational therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). This advancement represents a significant step toward improving accessibility, ease of administration, and overall treatment experience for patients living with ALS. The newly developed oral liquid formulation reflects Neurizon’s commitment to innovation that addresses the realworld challenges faced by people affected by ALS. For many patients, especially those experiencing bulbar onset or progressive difficulty swallowing, tablet-based medication can become increasingly hard to manage as the disease advances. The oral liquid formulation provides an important alternative, ensuring more patients can continue to benefit from NUZ-001 throughout their journey. Developed in direct response to feedback from patients and carers, this formulation reflects Neurizon’s belief that the patient voice should guide both trial design and treatment delivery. The key advantages of the liquid formulation include:     Improved ease of swallowing for patients with dysphagia or speech impairment Flexible dosing across a range of patient weights and tolerances Enteral (feeding tube) administration, ensuring continuity of treatment Simplified administration for caregivers and clinical teams Dr Michael Thurn, Managing Director and Chief Executive Officer, commented: “As ALS progresses, patients face increasing challenges with day-to-day activities, including something as fundamental as swallowing. This innovation is about flexibility, inclusion, and staying aligned with the needs of people living with ALS. Developing a successful oral liquid formulation - especially for a therapeutic like NUZ-001 targeting a vulnerable patient population - requires careful consideration of physical, chemical, and compatibility factors to ensure stability, bioavailability, and patient usability. By offering NUZ-001 in a liquid form, we’re ensuring that more patients can benefit from the therapy throughout all stages of disease progression.” The development of the liquid formulation also marks the launch of a life cycle management (LCM) strategy for NUZ001. LCM transforms a drug from a single-asset product into a long-term, scalable treatment platform, enhancing both patient value and commercial success. By strategically evolving the product, Neurizon aims to maximise patient impact, support long-term commercial growth, and drive innovation well beyond the original patent expiry. Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Next Steps The liquid formulation is currently being integrated into Neurizon’s ongoing clinical development program for NUZ001 and will be evaluated for bioequivalence and patient acceptability alongside the standard tablet form. This human bioequivalence study is scheduled to commence in H1 CY 2026. Neurizon remains committed to advancing accessible, patient-informed therapeutic solutions that reflect the lived experience of those affected by ALS. -ENDSThis announcement has been authorized for release by the Board of Neurizon Therapeutics Limited. For further information, please contact: Dr. Michael Thurn Managing Director and Chief Execufive Officer Neurizon Therapeufics Limited enquiries@neurizon.com +61 (3) 9692 7222 Lidija Damjanovic Head of Markefing and Corporate Affairs Neurizon Therapeufics Limited lidija@neurizon.com +61 (0) 425 700 504 Released through: Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538 About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. Neurizon Investor Hub We encourage you to ufilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This plafform offers an opportunity to submit quesfions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit hftps://investorhub.neurizon.com Neurizon® is a registered trademark of Neurizon Therapeutics Limited Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222